AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)
Completed
- Conditions
- Heart Failure
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 283
- Registration Number
- NCT05465213
- Locations
- 🇵🇹
Research Site, Vila Real, Portugal
Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal Insufficiency
Completed
- Conditions
- Hyperkalaemia
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 887
- Registration Number
- NCT05462119
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Research Site, Zhengzhou, China
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT05459688
- Locations
- 🇺🇸
Research Site, Manassas, Virginia, United States
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Phase 1
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell LungTriple Negative Breast Cancer
- Interventions
- Drug: Datopotamab Deruxtecan (Dato-DXd)
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 119
- Registration Number
- NCT05460273
- Locations
- 🇨🇳
Research Site, Wuhan, China
A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT05457270
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
Phase 4
Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 43
- Registration Number
- NCT05457257
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia
Recruiting
- Conditions
- NSCLC, Non-small-cell Lung Carcinoma
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT05456867
- Locations
- 🇷🇺
Research Site, Yuzhno-Sakhalinsk, Russian Federation
Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)
Recruiting
- Conditions
- Life Threatening BleedingFactor Xa Inhibitor
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT05454787
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease
Phase 1
Completed
- Conditions
- Crohns DiseaseHealthy Subjects
- Interventions
- Biological: Placebo
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 112
- Registration Number
- NCT05452304
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Phase 3
Active, not recruiting
- Conditions
- Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 594
- Registration Number
- NCT05450692
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath